Table 2 Pharmacokinetic parameters from single-dose administration studies of oral statins, including calculated average concentration in plasma (Css,av, using Eq. 1), and the corresponding expected vitreal concentrations (Calc. Cv, using Eq. 3).

From: Statins for the prevention of proliferative vitreoretinopathy: cellular responses in cultured cells and clinical statin concentrations in the vitreous

Drug

Dose

(mg/d)

fua

Cmax

(ng/mL)

AUC0−∞

(ng/mL)

n

Country

Css,av

(ng/mL)

Ref

Calc. Cv

(ng/mL)

Measured Cv (ng/mL)

Range

Average

SD

n

Simvastatin

40

0.05

9.8

40.32

17

China

1.68

20

0.084

0.027

0.073

0.048

0.017

3

Atorvastatin

10

 

3.2

11.67

24

Jordan

0.49

21

0.024

     

0.02

10.3

55.38

73

India

9.67

22

0.046

  

0.104

 

1

 

17.1

117.13

24

Turkey

2.31

23

0.098

     

20

 

5.1

58.60b,c

12

USA

4.88

24

0.049

     
 

10.8

44.51

45

China

1.85

25

0.037

0.053

0.217

0.135

0.116

2

 

15.4

183.00b

16

UK

7.63

26

0.153

     

40

 

6.9

98.70

18

USA

4.11

27

0.082

     
 

13.4

54.20

10

Finland

2.26

28

0.045

  

0.207

 

1

 

12.7

61.40

12

Finland

2.56

29

0.051

     

Rosuvastatin

10

0.12

10.8

102.59

12

China

4.27

30

0.513

  

0.055

 

1

 

4.5

48.39

18

Germany

2.02

31

0.242

     

20

 

19.2

176.59

12

Chinese

7.36

30

0.883

0.052

0.316

0.129

0.092

4

 

6.1

63.10

6

UK

2.62

32

0.314

     
  1. The measured Cv range, average, standard deviation (SD) from patients measured in the present study on the same oral statin treatment. Fu: free fraction of drug in plasma, Cmax: maximum drug concentration in plasma, AUC0−∞: area under the drug concentration curve from time 0 to infinity, n: number of participants in the clinical study.
  2. aFrom the summary of product characteristics document.
  3. bThe analytical method to measure the concentrations of drug in the plasma samples was based on bioassay that may be inaccurate.
  4. cAUC from 0 to 24 h.
Back to article page